Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for cancer and autoimmune diseases, has several upcoming catalysts to watch, including new data presentations at Digestive Disease Week (DDW) 2026, being held May 2-5, 2026, and multiple readouts and trial starts in the second half of 2026.
The company plans to present final results from its Phase 1 healthy-volunteer study of XmAb942, an extended half-life anti-TL1A antibody, at DDW 2026 in Chicago. Xencor will also share preclinical characterization data for XmAb412, a TL1A x IL23p19 bispecific antibody designed to target key inflammatory pathways in inflammatory bowel disease.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.